International Journal of Clinical Research

Objective To explore the clinical application of Niaoduqing Granules in controlling hyperphosphatemia in hemodialysis patients. Methods A retrospective analysis was conducted on 70 patients with chronic renal failure admitted to our hospital from January 2022 to January 2023 as the research objects. They were divided into the control group (treated with hemodialysis alone) and the treatment group (treated with Niaoduqing Granules on the basis of the control group), with 35 cases in each group, according to the treatment methods. The therapeutic effects of the two groups were compared. Results There were no statistically significant differences in serum creatinine and blood urea nitrogen between the two groups before dialysis and after 6 months and 12 months of treatment (all P > 0.05). There were statistically significant differences in blood calcium and blood phosphorus before and after treatment in the treatment group (all P < 0.05), and compared with the control group, P < 0.05. Moreover, the blood pressure and heart rate indicators of the patients in the treatment group after treatment were better than those of the patients in the control group (P < 0.05). Conclusion Niaoduqing Granules combined with hemodialysis in the treatment of maintenance dialysis patients with chronic renal failure has a significant effect and has a very significant therapeutic effect on regulating calcium and phosphorus metabolism, which is worthy of promotion.

Niaoduqing Granules; Hemodialysis patients; Control effect of hyperphosphatemia; Clinical research